Zacks: Brokerages Anticipate Ginkgo Bioworks Holdings Inc (NYSE:DNA) Will Announce Quarterly Sales of $55.25 Million

Analysts expect Ginkgo Bioworks Holdings Inc (NYSE:DNA) to report $55.25 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Ginkgo Bioworks’ earnings, with the lowest sales estimate coming in at $53.50 million and the highest estimate coming in at $57.00 million. The firm is expected to report its next earnings results on Monday, February 21st.

According to Zacks, analysts expect that Ginkgo Bioworks will report full year sales of $220.90 million for the current fiscal year, with estimates ranging from $218.80 million to $223.00 million. For the next year, analysts expect that the business will post sales of $271.35 million, with estimates ranging from $244.00 million to $298.70 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Ginkgo Bioworks.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings results on Monday, November 15th. The company reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.03). The company had revenue of $77.61 million during the quarter, compared to analysts’ expectations of $46.00 million.

DNA has been the topic of a number of analyst reports. William Blair initiated coverage on Ginkgo Bioworks in a research note on Tuesday, October 12th. They issued an “outperform” rating on the stock. Raymond James set a $14.50 target price on Ginkgo Bioworks and gave the stock an “outperform” rating in a research report on Friday, November 12th. Finally, HSBC started coverage on Ginkgo Bioworks in a report on Monday, September 20th. They issued a “buy” rating and a $14.00 price target for the company.

Several large investors have recently made changes to their positions in DNA. Close Asset Management Ltd purchased a new stake in shares of Ginkgo Bioworks during the third quarter worth $25,000. Mint Tower Capital Management B.V. purchased a new stake in shares of Ginkgo Bioworks during the third quarter worth $68,000. US Bancorp DE purchased a new stake in shares of Ginkgo Bioworks during the third quarter worth $93,000. ARS Wealth Advisors Group LLC purchased a new stake in shares of Ginkgo Bioworks during the third quarter worth $116,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Ginkgo Bioworks during the third quarter worth $116,000.

Shares of Ginkgo Bioworks stock traded down $0.10 during trading on Friday, reaching $12.00. The company’s stock had a trading volume of 3,350,283 shares, compared to its average volume of 5,160,824. The company has a debt-to-equity ratio of 0.01, a current ratio of 20.05 and a quick ratio of 20.01. Ginkgo Bioworks has a 12-month low of $8.90 and a 12-month high of $15.86. The business’s 50 day simple moving average is $12.62.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.

Recommended Story: What are the advantages to having securities held in street name?

Get a free copy of the Zacks research report on Ginkgo Bioworks (DNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.